{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:12:04Z","timestamp":1783581124925,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"The Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","award":["541001009"],"award-info":[{"award-number":["541001009"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The clinical landscape of prostate biopsy (PB) is evolving with changes in procedures and techniques. Moreover, antibiotic resistance is increasing and influences the efficacy of pre-biopsy prophylactic regimens. Therefore, increasing antibiotic resistance may impact on clinical care, which probably results in differences between hospitals. The objective of our study is to determine the (variability in) current practices of PB in the Netherlands and to gain insight into Dutch urologists\u2019 perceptions of fluoroquinolone resistance and biopsy related infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An online questionnaire was prepared using SurveyMonkey\u00ae platform and distributed to all 420 members of the Dutch Association of Urology, who work in 81 Dutch hospitals. Information about PB techniques and periprocedural antimicrobial prophylaxis was collected. Urologists\u2019 perceptions regarding pre-biopsy antibiotic prophylaxis in an era of antibiotic resistance was assessed. Descriptive statistical analysis was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred sixty-one responses (38.3%) were analyzed representing 65 (80.3%) of all Dutch hospitals performing PB. Transrectal ultrasound guided prostate biopsy (TRUSPB) was performed in 64 (98.5%) hospitals. 43.1% of the hospitals (also) used other image-guided biopsy techniques. Twenty-three different empirical prophylactic regimens were reported among the hospitals. Ciprofloxacin was most commonly prescribed (84.4%). The duration ranged from one pre-biopsy dose (59.4%) to 5 days extended prophylaxis. 25.2% of the urologists experienced ciprofloxacin resistance as a current problem in the prevention of biopsy related infections and 73.6% as a future problem.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There is a wide variation in practice patterns among Dutch urologists. TRUSPB is the most commonly used biopsy technique, but other image-guided biopsy techniques are increasingly used. Antimicrobial prophylaxis is not standardized and prolonged prophylaxis is common. The wide variation in practice patterns and lack of standardization underlines the need for evidence-based recommendations to guide urologists in choosing appropriate antimicrobial prophylaxis for PB in the context of increasing antibiotic resistance.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12894-020-00592-8","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T08:02:44Z","timestamp":1584000164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prostate biopsy techniques and pre-biopsy prophylactic measures: variation in current practice patterns in the Netherlands"],"prefix":"10.1186","volume":"20","author":[{"given":"Sofie C. M.","family":"Tops","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evert L.","family":"Koldewijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita M. P.","family":"Huis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kolwijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiman F. L.","family":"Wertheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies E. J. L.","family":"Hulscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P. Michiel","family":"Sedelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"592_CR1","unstructured":"Volksgezondheidenzorg.info [Updated 12th July 2017. RIVM Bilthoven: [Available from: https:\/\/www.volksgezondheidenzorg.info\/onderwerp\/prostaatkanker\/cijfers-context\/huidige-situatie#!node-prevalentie-prostaatkanker."},{"issue":"1","key":"592_CR2","first-page":"124","volume":"65","author":"N Mottet","year":"2019","unstructured":"Mottet N, van den Bergh R, Briers E, Cornford P, De Santis M, Fanti S, et al. Guidelines on prostate cancer. Eur Assoc Urol. 2019;65(1):124.","journal-title":"Eur Assoc Urol"},{"issue":"4","key":"592_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","volume":"75","author":"O Wegelin","year":"2019","unstructured":"Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, et al. The FUTURE trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate Cancer in patients with prior negative biopsies. Eur Urol. 2019;75(4):582\u201390.","journal-title":"Eur Urol"},{"issue":"4","key":"592_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.juro.2008.01.068","volume":"179","author":"JS Wolf Jr","year":"2008","unstructured":"Wolf JS Jr, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179(4):1379\u201390.","journal-title":"J Urol"},{"key":"592_CR5","unstructured":"Bonkat G, Bartoletti RR, Bruy\u00e8re F, Cai T, Geerlings SE, K\u00f6ves B, et al. EAU Guidelines on Urological Infections 2019. Uroweb. Available from: http:\/\/uroweb.org\/guideline\/urological-infections\/."},{"key":"592_CR6","unstructured":"van Haarst EP, Bootsma AMJ, Elzevier HW, Froeling FMJA, Geerlings SE, Jansen FH, et al. NVU richtlijn: Bacteri\u00eble urineweginfecties bij adolescenten en volwassenen. 2009. Available from: https:\/\/www.nvu.nl\/Portals\/_default\/Skins\/NVU\/DocumentHandlerPublic.ashx?id=817db8b4-e657-40d0-bc20-52ebc1d286ff&filename=bijlage%20C58%20urineweginfectie%202009.pdf."},{"key":"592_CR7","volume-title":"SWAB Richtlijn Peri-operatieve profylaxe","author":"Antibioticabeleid SW","year":"2018","unstructured":"Antibioticabeleid SW. SWAB Richtlijn Peri-operatieve profylaxe. 2018."},{"key":"592_CR8","unstructured":"De Greef SC, Mouton JW, Schoffelen AF, Verduin CM. NethMap 2019: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2018. RIVM Bilthoven; 2019. Available from: https:\/\/www.rivm.nl\/sites\/default\/files\/2019-09\/Nethmap%20Maran%202019%20beveiligd.pdf."},{"key":"592_CR9","first-page":"5392107","volume":"2016","author":"J Van Besien","year":"2016","unstructured":"Van Besien J, Uvin P, Van den Abeele AM, Merckx L. Prevalence, risk factors, and clinical relevance of Fluoroquinolone-resistant organisms in rectal cultures: should we target antibiotic prophylaxis prior to prostate biopsy? Ther Adv Urol. 2016;2016:5392107.","journal-title":"Ther Adv Urol"},{"key":"592_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fsurg.2018.00002","volume":"5","author":"K Boehm","year":"2018","unstructured":"Boehm K, Siegel FP, Schneidewind L, Kranz J, Spachmann P, Frank T, et al. Antibiotic prophylaxis in prostate biopsies: contemporary practice patterns in Germany. Front Surg. 2018;5:2.","journal-title":"Front Surg"},{"issue":"6","key":"592_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/00365599.2012.691111","volume":"46","author":"S Carlsson","year":"2012","unstructured":"Carlsson S, Bratt O, Stattin P, Egevad L. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish urology network. Scand J Urol Nephrol. 2012;46(6):405\u201310.","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"592_CR12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/0974-7796.152017","volume":"7","author":"P Davis","year":"2015","unstructured":"Davis P, Paul E, Grummet J. Current practice of prostate biopsy in Australia and New Zealand: a survey. Urol Ann. 2015;7(3):315\u20139.","journal-title":"Urol Ann"},{"issue":"6","key":"592_CR13","first-page":"6573","volume":"19","author":"JH Hillelsohn","year":"2012","unstructured":"Hillelsohn JH, Duty B, Blute ML Jr, Okhunov Z, Kashan M, Moldwin R, et al. Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures. Can J Urol. 2012;19(6):6573\u20137.","journal-title":"Can J Urol"},{"issue":"1","key":"592_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11845-011-0774-5","volume":"181","author":"LG Smyth","year":"2012","unstructured":"Smyth LG, Mulvin DW. Antibiotic prophylaxis for transrectal ultrasound biopsy of the prostate in Ireland. Ir J Med Sci. 2012;181(1):33\u20135.","journal-title":"Ir J Med Sci"},{"issue":"1","key":"592_CR15","doi-asserted-by":"publisher","first-page":"ofv002","DOI":"10.1093\/ofid\/ofv002","volume":"2","author":"JR Johnson","year":"2015","unstructured":"Johnson JR, Polgreen PM, Beekmann SE. Transrectal prostate biopsy-associated prophylaxis and infectious complications: report of a query to the emerging infections network of the infectious diseases society of america. Open Forum Infect Dis. 2015;2(1):ofv002.","journal-title":"Open Forum Infect Dis"},{"key":"592_CR16","unstructured":"Grabe M, Bartoletti R, Bjerklund-Johansen TE, \u00c7ek HM, Pickard RS, Tenke P, et al. EAU Guidelines on Urological Infections 2015. Uroweb. Available from: https:\/\/uroweb.org\/wp-content\/uploads\/19-Urological-infections_LR2.pdf."},{"key":"592_CR17","unstructured":"ZorgkaartNederland. Pati\u00ebntenfederatie Nederland. [Available from: https:\/\/www.zorgkaartnederland.nl\/uroloog."},{"issue":"1","key":"592_CR18","first-page":"124","volume":"65","author":"N Mottet","year":"2015","unstructured":"Mottet N, Bellmunt J, Briers E, van den RCN B, Bolla M, van NJ C, et al. Guidelines on prostate cancer. Eur Assoc Urol. 2015;65(1):124.","journal-title":"Eur Assoc Urol"},{"issue":"1","key":"592_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouviere","year":"2019","unstructured":"Rouviere O, Puech P, Renard-Penna R, Claudon M, Roy C, Mege-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100\u20139.","journal-title":"Lancet Oncol"},{"issue":"7","key":"592_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1001\/jamasurg.2019.0569","volume":"154","author":"W Branch-Elliman","year":"2019","unstructured":"Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of Duration and Type of Surgical Prophylaxis With Antimicrobial-Associated Adverse Events. JAMA Surg. 2019;154(7):590.","journal-title":"JAMA Surg"},{"issue":"7","key":"592_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00345-018-2217-7","volume":"36","author":"S Scott","year":"2018","unstructured":"Scott S, Harris PN, Williamson DA, Liss MA, Doi SAR, Roberts MJ. The effectiveness of targeted relative to empiric prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy: a meta-analysis. World J Urol. 2018;36(7):1007\u201317.","journal-title":"World J Urol"},{"issue":"12","key":"592_CR22","first-page":"1621","volume":"92","author":"P Kanjanawongdeengam","year":"2009","unstructured":"Kanjanawongdeengam P, Viseshsindh W, Santanirand P, Prathombutr P, Nilkulwattana S. Reduction in bacteremia rates after rectum sterilization before transrectal, ultrasound-guided prostate biopsy: a randomized controlled trial. J Med Assoc Thail. 2009;92(12):1621\u20136.","journal-title":"J Med Assoc Thail"},{"issue":"2","key":"592_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0090-4295(81)90425-8","volume":"18","author":"RW Brown","year":"1981","unstructured":"Brown RW, Warner JJ, Turner BI, Harris LF, Alford RH. Bacteremia and bacteriuria after transrectal prostatic biopsy. Urology. 1981;18(2):145\u20138.","journal-title":"Urology"},{"issue":"3","key":"592_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF02550403","volume":"22","author":"MD Melekos","year":"1990","unstructured":"Melekos MD. Efficacy of prophylactic antimicrobial regimens in preventing infectious complications after transrectal biopsy of the prostate. Int Urol Nephrol. 1990;22(3):257\u201362.","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"592_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0022-5347(17)53730-1","volume":"127","author":"JR Sharpe","year":"1982","unstructured":"Sharpe JR, Sadlowski RW, Finney RP, Branch WT, Hanna JE. Urinary tract infection after transrectal needle biopsy of the prostate. J Urol. 1982;127(2):255\u20136.","journal-title":"J Urol"},{"issue":"4","key":"592_CR26","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.juro.2012.09.121","volume":"189","author":"Z Abughosh","year":"2013","unstructured":"Abughosh Z, Margolick J, Goldenberg SL, Taylor SA, Afshar K, Bell R, et al. A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol. 2013;189(4):1326\u201331.","journal-title":"J Urol"},{"issue":"2","key":"592_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5812\/iranjradiol.7561","volume":"9","author":"M Ghafoori","year":"2012","unstructured":"Ghafoori M, Shakiba M, Seifmanesh H, Hoseini K. Decrease in infection rate following use of povidone-iodine during transrectal ultrasound guided biopsy of the prostate: a double blind randomized clinical trial. Iran J Radiol. 2012;9(2):67\u201370.","journal-title":"Iran J Radiol"},{"issue":"3","key":"592_CR28","first-page":"209","volume":"25","author":"KL Lo","year":"2019","unstructured":"Lo KL, Chui KL, Leung CH, Ma SF, Lim K, Ng T, et al. Outcomes of transperineal and transrectal ultrasound-guided prostate biopsy. Hong Kong Med J. 2019;25(3):209\u201315.","journal-title":"Hong Kong Med J"},{"issue":"14","key":"592_CR29","doi-asserted-by":"publisher","first-page":"23322","DOI":"10.18632\/oncotarget.15056","volume":"8","author":"J Xue","year":"2017","unstructured":"Xue J, Qin Z, Cai H, Zhang C, Li X, Xu W, et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget. 2017;8(14):23322\u201336.","journal-title":"Oncotarget"},{"issue":"1","key":"592_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12894-019-0539-4","volume":"19","author":"GL Huang","year":"2019","unstructured":"Huang GL, Kang CH, Lee WC, Chiang PH. Comparisons of cancer detection rate and complications between transrectal and transperineal prostate biopsy approaches - a single center preliminary study. BMC Urol. 2019;19(1):101.","journal-title":"BMC Urol"},{"issue":"4","key":"592_CR31","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ucl.2017.07.002","volume":"44","author":"J Grummet","year":"2017","unstructured":"Grummet J. How to biopsy: Transperineal versus Transrectal, saturation versus targeted, What's the evidence? Urol Clin North Am. 2017;44(4):525\u201334.","journal-title":"Urol Clin North Am"},{"issue":"5","key":"592_CR32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/bju.14853","volume":"124","author":"W Venderink","year":"2019","unstructured":"Venderink W, van Luijtelaar A, van der Leest M, Barentsz JO, Jenniskens SFM, Sedelaar MJP, et al. Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men. BJU Int. 2019;124(5):775\u201384.","journal-title":"BJU Int"},{"issue":"19","key":"592_CR33","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-Cancer diagnosis. N Engl J Med. 2018;378(19):1767\u201377.","journal-title":"N Engl J Med"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-020-00592-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T13:44:15Z","timestamp":1666100655000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-020-00592-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1186\/s12894-020-00592-8","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"26 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No individual person\u2019s data were collected. All data were anonymized and collected in accordance to the General Data Protection Regulation (GDPR) which standardizes data protection law across all EU countries. Because all data were collected via an anonymous online survey on a voluntary base, approvement of the ethical committee is not required as per local legislation. By accepting the invitation to complete the online survey, all participants provided their informed consent to take part in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None of the contributing authors have any conflicts of interest, except that this research was funded by The Netherlands Organisation for Health Research and Development (ZonMw), grant number 541001009.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}